Viral hepatitis and immunotherapy outcome in advanced hepatocellular carcinoma: A comprehensive umbrella review of 15 meta-analyses
- 7 March 2026
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 221, 105248
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Quantitative evaluation of the efficacy and safety of first-line systemic therapies for advanced hepatocellular carcinomaEuropean Journal of Clinical Pharmacology, 2024
- Is atezolizumab plus bevacizumab as first-line therapy for unresectable hepatocellular carcinoma superior to lenvatinib? a systematic review and meta‑analysisEuropean Journal of Clinical Pharmacology, 2024
- Lenvatinib Versus Atezolizumab Plus Bevacizumab in the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Meta-Analysis of Real-World StudiesTargeted Oncology, 2024
- Comparison of the effects of lenvatinib and sorafenib on survival in patients with advanced hepatocellular carcinoma: A systematic review and meta-analysisClinics and Research in Hepatology and Gastroenterology, 2022
- Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysisInternational Immunopharmacology, 2022
- Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular CarcinomaJAMA Network Open, 2021
- Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinomaJournal of Hepatology, 2020
- Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With SorafenibJAMA Oncology, 2020
- Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 updateHepatology International, 2017
- AASLD guidelines for the treatment of hepatocellular carcinomaHepatology, 2017